How we manage follicular lymphoma von Hiddemann, W, Cheson, B D

Volltext

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients von Mato, A.R., Hill, B.T., Lamanna, N., Barr, P.M., Ujjani, C.S., Brander, D.M., Howlett, C., Skarbnik, A.P., Cheson, B.D., Zent, C.S., Pu, J.J., Kiselev, P., Foon, K., Lenhart, J., Henick Bachow, S., Winter, A.M., Cruz, A.-L., Claxton, D.F., Goy, A., Daniel, C., Isaac, K., Kennard, K.H., Timlin, C., Fanning, M., Gashonia, L., Yacur, M., Svoboda, J., Schuster, S.J., Nabhan, C.

Volltext

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 von Bartlett, NL, Niedzwiecki, D, Johnson, JL, Friedberg, JW, Johnson, KB, van Besien, K, Zelenetz, AD, Cheson, BD, Canellos, GP

Volltext

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) von Martin, P., Jung, S.-H., Pitcher, B., Bartlett, N.L., Blum, K.A., Shea, T., Hsi, E.D., Ruan, J., Smith, S.E., Leonard, J.P., Cheson, B.D.

Volltext

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes von Pfeifer, M, Zheng, B, Erdmann, T, Koeppen, H, McCord, R, Grau, M, Staiger, A, Chai, A, Sandmann, T, Madle, H, Dörken, B, Chu, Y-W, Chen, A I, Lebovic, D, Salles, G A, Czuczman, M S, Palanca-Wessels, M C, Press, O W, Advani, R, Morschhauser, F, Cheson, B D, Lenz, P, Ott, G, Polson, A G, Mundt, K E, Lenz, G

Volltext

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma von Crump, M., Coiffier, B., Jacobsen, E. D., Sun, L., Ricker, J. L., Xie, H., Frankel, S. R., Randolph, S. S., Cheson, B. D.

Volltext

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma von Leonard, JP, Friedberg, JW, Younes, A, Fisher, D, Gordon, LI, Moore, J, Czuczman, M, Miller, T, Stiff, P, Cheson, BD, Forero-Torres, A, Chieffo, N, McKinney, B, Finucane, D, Molina, A

Volltext

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience von Hong, F., Habermann, T.M., Gordon, L.I., Hochster, H., Gascoyne, R.D., Morrison, V.A., Fisher, R.I., Bartlett, N.L., Stiff, P.J., Cheson, B.D., Crump, M., Horning, S.J., Kahl, B.S.

Volltext

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront... von Czuczman, M.S., Leonard, J.P., Jung, S., Johnson, J.L., Hsi, E.D., Byrd, J.C., Cheson, B.D.

Volltext

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia von Cheson, Bruce D., Greenberg, Peter L., Bennett, John M., Lowenberg, Bob, Wijermans, Pierre W., Nimer, Stephen D., Pinto, Antonio, Beran, Miloslav, de Witte, Theo M., Stone, Richard M., Mittelman, Moshe, Sanz, Guillermo F., Gore, Steven D., Schiffer, Charles A., Kantarjian, Hagop

Volltext

Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory? von Cheson, B.D

Volltext

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism... von Blum, K.A., Jung, S.-H., Johnson, J.L., Lin, T.S., Hsi, E.D., Lucas, D.M., Byrd, J.C., Cheson, B.D., Bartlett, N.L.

Volltext

Report of an international working group to standardize response criteria for myelodysplastic syndromes von Cheson, Bruce D., Bennett, John M., Kantarjian, Hagop, Pinto, Antonio, Schiffer, Charles A., Nimer, Stephen D., Löwenberg, Bob, Beran, Miroslav, de Witte, Theo M., Stone, Richard M., Mittelman, Moshe, Sanz, Guillermo F., Wijermans, Pierre W., Gore, Steven, Greenberg, Peter L.

Volltext

National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment von Cheson, Bruce D., Bennett, John M., Grever, Michael, Kay, Neil, Keating, Michael J., O’Brien, Susan, Rai, Kanti R.

Volltext

Infectious and immunosuppressive complications of purine analog therapy von CHESON, B. D

Volltext

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront... von Czuczman, M S, Leonard, J P, Jung, S, Johnson, J L, Hsi, E D, Byrd, J C, Cheson, B D

Volltext

Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias von CHESON, B. D, VENA, D. A, BARRETT, J, FREIDLIN, B

Volltext

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma von Ujjani, C., Wang, H., Broome, C., Gopal, A., Lai, C., Warren, E., Shadman, M., Smith, S. D., Lynch, R., Swanson, N., Grossfeld, T., Sorensen, T., Cheson, B. D., Dunleavy, K.

Volltext

A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES von Cheson, B. D., Morschhauser, F., Assouline, S. E., Michallet, A., Tani, M., Paris, G., Sun, W., Atwal, S. K., Hong, W., Sarkozy, C.

Volltext

New response criteria for lymphomas in clinical trials von Cheson, B. D.

Volltext